Related Experiment Video
Updated: Aug 11, 2026
14:10
Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies
Published on: January 31, 2013
[Hypokalemic myopathy in cats]
1I. Medizinischen Tierklinik, Ludwig-Maximilians-Universität München.
Tierarztliche Praxis
|April 1, 1995
Summary
Hypokalemic myopathy in cats, often linked to diabetic ketoacidosis, typically resolves with potassium supplementation within days. Some cats may require ongoing potassium therapy.
Area of Science:
- Veterinary Medicine
- Comparative Pathology
- Animal Physiology
Context:
- Hypokalemic myopathy is a clinical condition characterized by muscle weakness due to low potassium levels.
- Diabetic ketoacidosis (DKA) is a serious complication of diabetes mellitus.
- Understanding the causes and resolution of hypokalemic myopathy in cats is crucial for effective treatment.
Purpose:
- To describe the clinical signs, laboratory findings, and disease course of hypokalemic myopathy in a cohort of ten cats.
- To investigate the role of diabetic ketoacidosis and its treatment in the development of hypokalemia.
- To determine the duration of potassium supplementation required for normokalemia and resolution of clinical signs.
Summary:
- Ten cats with hypokalemic myopathy were studied, with nine experiencing temporary hypokalemia secondary to severe diabetic ketoacidosis and its treatment.
- Normokalemia was restored in nine cats within three to seven days of potassium substitution.
- Clinical signs of hypokalemic myopathy resolved rapidly, within one to four days, following potassium supplementation.
Impact:
- This study highlights the transient nature of hypokalemia in many cats with diabetic ketoacidosis, emphasizing the importance of monitoring and correcting potassium levels.
- Provides valuable insights into the management and prognosis of hypokalemic myopathy in feline patients.
- Contributes to the understanding of electrolyte imbalances in cats with metabolic diseases.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
01:25Diabetic Ketoacidosis l: Introduction
DefinitionDiabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus, characterized by a triad of hyperglycemia (blood glucose >250 mg/dL), ketonemia or ketonuria, and metabolic acidosis (arterial pH <7.30 and serum bicarbonate <18 mEq/L). It results from insulin deficiency combined with elevated levels of counterregulatory hormones—glucagon, catecholamines, cortisol, and growth hormone—leading to increased lipolysis, hepatic ketone production, and...
01:22Diabetic Ketoacidosis ll: Pathophysiology
Diabetic ketoacidosis (DKA) is a metabolic emergency characterized by hyperglycemia, ketonemia, and metabolic acidosis. It results from severe insulin deficiency and an excess of counterregulatory hormones, leading to uncontrolled lipolysis, ketogenesis, and widespread electrolyte and fluid disturbances.Pathophysiology The central event in DKA is a profound loss of insulin action. Without insulin, glucose uptake in insulin-dependent tissues is impaired, while hepatic glucose production...